Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. (Q48215164)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. |
scientific article |
Statements
1 reference
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. (English)
1 reference
1 reference
Lecia V Sequist
1 reference
Vera Hirsh
1 reference
Martin Schuler
1 reference
Nobuyuki Yamamoto
1 reference
Kenneth J O'Byrne
1 reference
Tony S K Mok
1 reference
Victoria Zazulina
1 reference
Mehdi Shahidi
1 reference
Juliane Lungershausen
1 reference
Dan Massey
1 reference
Michael Palmer
1 reference
1 July 2013
1 reference
1 reference
31
1 reference
27
1 reference
3342-3350
1 reference
Identifiers
1 reference
1 reference